{"symbol":"SZ002262","secucode":"002262.SZ","items":[{"title":"诺和诺德26亿美元买下恒瑞医药周口服减肥药；阿斯利康将出资20亿美元战略投资Summit丨医药早参","summary":"丨2026年9月30日星期三丨NO.1恒瑞医药：将周口服减肥药许可给诺和诺德，潜在总交易额最高可达26亿美元9月29日，恒瑞医药公告称，与诺和诺德达成协议，将恒瑞潜在每周一次口服给药的胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596有偿许可给诺和诺德。诺和诺德将获得HRS-1596在大中华地区以外的全球范围内开发、生产和商业化的独家权利。","source":null,"url":"http://finance.eastmoney.com/news/1354,202609303886886698.html","info_code":"NW202609303886886698","show_time_timestamp":1790722804000,"show_time":"2026-09-30 07:00:04","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202609303886886698.html","url":"http://finance.eastmoney.com/news/1354,202609303886886698.html","code":"202609303886886698","infoCode":"NW202609303886886698","recordId":null,"source":null,"title":"诺和诺德26亿美元买下恒瑞医药周口服减肥药；阿斯利康将出资20亿美元战略投资Summit丨医药早参","updateTime":0,"showDateTime":1790722804000,"publishDate":0,"sRatingName":null,"summary":"丨2026年9月30日星期三丨NO.1恒瑞医药：将周口服减肥药许可给诺和诺德，潜在总交易额最高可达26亿美元9月29日，恒瑞医药公告称，与诺和诺德达成协议，将恒瑞潜在每周一次口服给药的胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596有偿许可给诺和诺德。诺和诺德将获得HRS-1596在大中华地区以外的全球范围内开发、生产和商业化的独家权利。"}},{"title":"恩华药业：第七届董事会第十次会议决议公告","summary":"证券日报网讯9月29日，恩华药业发布公告称，公司于2026年9月29日召开第七届董事会第十次会议，审议通过《关于签署独占许可协议暨对外投资的议案》《关于参股公司GoodMoodHoldingsLimited增资的议案》。","source":null,"url":"http://finance.eastmoney.com/news/1349,202609293886712386.html","info_code":"NW202609293886712386","show_time_timestamp":1790687940000,"show_time":"2026-09-29 21:19:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202609293886712386.html","url":"http://finance.eastmoney.com/news/1349,202609293886712386.html","code":"202609293886712386","infoCode":"NW202609293886712386","recordId":null,"source":null,"title":"恩华药业：第七届董事会第十次会议决议公告","updateTime":0,"showDateTime":1790687940000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯9月29日，恩华药业发布公告称，公司于2026年9月29日召开第七届董事会第十次会议，审议通过《关于签署独占许可协议暨对外投资的议案》《关于参股公司GoodMoodHoldingsLimited增资的议案》。"}},{"title":"创新药又一利好！002262，睡眠新药授权出海，首付款1050万美元＋最高5亿美元里程碑款","summary":"恩华药业（SZ002262，股价21.50元，市值217.79亿元）9月29日盘后公告，公司与美国Somnivera,Inc.签订独占许可协议，拟将一款处于临床阶段、用于治疗睡眠障碍的自研1类创新药在全球（除中国大陆、港澳台地区外）的开发、生产和商业化独家权利授权给对方，并同步通过全资子公司香港恩华医药有限公司取得Somnivera公司15%股权。","source":null,"url":"http://stock.eastmoney.com/news/11215,202609293886641944.html","info_code":"NW202609293886641944","show_time_timestamp":1790686364000,"show_time":"2026-09-29 20:52:44","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202609293886641944.html","url":"http://stock.eastmoney.com/news/11215,202609293886641944.html","code":"202609293886641944","infoCode":"NW202609293886641944","recordId":null,"source":null,"title":"创新药又一利好！002262，睡眠新药授权出海，首付款1050万美元＋最高5亿美元里程碑款","updateTime":0,"showDateTime":1790686364000,"publishDate":0,"sRatingName":null,"summary":"恩华药业（SZ002262，股价21.50元，市值217.79亿元）9月29日盘后公告，公司与美国Somnivera,Inc.签订独占许可协议，拟将一款处于临床阶段、用于治疗睡眠障碍的自研1类创新药在全球（除中国大陆、港澳台地区外）的开发、生产和商业化独家权利授权给对方，并同步通过全资子公司香港恩华医药有限公司取得Somnivera公司15%股权。"}},{"title":"恩华药业签订5亿美元BD大单；华之杰拟切入半导体测试配套领域丨公告精选","summary":"今日焦点恩华药业：授予Somnivera一款治疗睡眠障碍的在研创新药独家权利有权获最高5.07亿美元里程碑付款恩华药业公告称，公司与Somnivera签订独占许可协议，授予其在除中国大陆、港澳台外的全球范围开发、生产和商业化一款在研药物独家权利。该在研药物是公司自主研发、具有自主知识产权的1类创新药，拟用于治疗睡眠障碍。","source":null,"url":"http://finance.eastmoney.com/news/1354,202609293886638945.html","info_code":"NW202609293886638945","show_time_timestamp":1790685840000,"show_time":"2026-09-29 20:44:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202609293886638945.html","url":"http://finance.eastmoney.com/news/1354,202609293886638945.html","code":"202609293886638945","infoCode":"NW202609293886638945","recordId":null,"source":null,"title":"恩华药业签订5亿美元BD大单；华之杰拟切入半导体测试配套领域丨公告精选","updateTime":0,"showDateTime":1790685840000,"publishDate":0,"sRatingName":null,"summary":"今日焦点恩华药业：授予Somnivera一款治疗睡眠障碍的在研创新药独家权利有权获最高5.07亿美元里程碑付款恩华药业公告称，公司与Somnivera签订独占许可协议，授予其在除中国大陆、港澳台外的全球范围开发、生产和商业化一款在研药物独家权利。该在研药物是公司自主研发、具有自主知识产权的1类创新药，拟用于治疗睡眠障碍。"}},{"title":"自研临床阶段睡眠药出海，恩华药业与Somnivera签署独占许可协议，将获1050万美元首付款","summary":"9月29日，恩华药业（002262）发布公告，公司与Somnivera,Inc.签署独占许可协议，授予Somnivera在除中国大陆、香港特别行政区、澳门特别行政区及台湾地区以外的全球范围内开发、生产和商业化一款处于临床阶段的拟用于治疗睡眠障碍的在研药物的独家权利。","source":null,"url":"http://stock.eastmoney.com/news/11215,202609293886620466.html","info_code":"NW202609293886620466","show_time_timestamp":1790683695000,"show_time":"2026-09-29 20:08:15","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202609293886620466.html","url":"http://stock.eastmoney.com/news/11215,202609293886620466.html","code":"202609293886620466","infoCode":"NW202609293886620466","recordId":null,"source":null,"title":"自研临床阶段睡眠药出海，恩华药业与Somnivera签署独占许可协议，将获1050万美元首付款","updateTime":0,"showDateTime":1790683695000,"publishDate":0,"sRatingName":null,"summary":"9月29日，恩华药业（002262）发布公告，公司与Somnivera,Inc.签署独占许可协议，授予Somnivera在除中国大陆、香港特别行政区、澳门特别行政区及台湾地区以外的全球范围内开发、生产和商业化一款处于临床阶段的拟用于治疗睡眠障碍的在研药物的独家权利。"}}]}